Mutations in SETD2 cause a novel overgrowth condition

Background Overgrowth conditions are a heterogeneous group of disorders characterised by increased growth and variable features, including macrocephaly, distinctive facial appearance and various degrees of learning difficulties and intellectual disability. Among them, Sotos and Weaver syndromes are clinically well defined and due to heterozygous mutations in NSD1 and EZH2, respectively. NSD1 and EZH2 are both histone-modifying enzymes. These two epigenetic writers catalyse two specific post-translational modifications of histones: methylation of histone 3 lysine 36 (H3K36) and lysine 27 (H3K27). We postulated that mutations in writers of these two chromatin marks could cause overgrowth conditions, resembling Sotos or Weaver syndromes, in patients with no NSD1 or EZH2 abnormalities. Methods We analysed the coding sequences of 14 H3K27 methylation-related genes and eight H3K36 methylation-related genes using a targeted next-generation sequencing approach in three Sotos, 11 ‘Sotos-like’ and two Weaver syndrome patients. Results We identified two heterozygous mutations in the SETD2 gene in two patients with ‘Sotos-like’ syndrome: one missense p.Leu1815Trp de novo mutation in a boy and one nonsense p.Gln274* mutation in an adopted girl. SETD2 is non-redundantly responsible for H3K36 trimethylation. The two probands shared similar clinical features, including postnatal overgrowth, macrocephaly, obesity, speech delay and advanced carpal ossification. Conclusions Our results illustrate the power of targeted next-generation sequencing to identify rare disease-causing variants. We provide a compelling argument for Sotos and Sotos-like syndromes as epigenetic diseases caused by loss-of-function mutations of epigenetic writers of the H3K36 histone mark.

[1]  Katrina Tatton-Brown,et al.  Mutations in the DNA methyltransferase gene, DNMT3A, cause an overgrowth syndrome with intellectual disability , 2014, Nature Genetics.

[2]  Yuchen Jiao,et al.  Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas , 2014, Genes, chromosomes & cancer.

[3]  N. Rahman,et al.  The NSD1 and EZH2 Overgrowth Genes, Similarities and Differences , 2013, American journal of medical genetics. Part C, Seminars in medical genetics.

[4]  David T. W. Jones,et al.  Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas , 2013, Acta Neuropathologica.

[5]  Yoo Jin Jung,et al.  The transcriptional landscape and mutational profile of lung adenocarcinoma , 2012, Genome research.

[6]  C. Bountra,et al.  Epigenetic protein families: a new frontier for drug discovery , 2012, Nature Reviews Drug Discovery.

[7]  E. Greer,et al.  Histone methylation: a dynamic mark in health, disease and inheritance , 2012, Nature Reviews Genetics.

[8]  L. Zitvogel,et al.  Inflammasomes in carcinogenesis and anticancer immune responses , 2012, Nature Immunology.

[9]  E. Wagner,et al.  Understanding the language of Lys36 methylation at histone H3 , 2012, Nature Reviews Molecular Cell Biology.

[10]  Steven J. M. Jones,et al.  Mutations in EZH2 cause Weaver syndrome. , 2012, American journal of human genetics.

[11]  E. di Luccio,et al.  Cancers and the NSD family of histone lysine methyltransferases. , 2011, Biochimica et biophysica acta.

[12]  Paul Flicek,et al.  The functional spectrum of low-frequency coding variation , 2011, Genome Biology.

[13]  Nada Jabado,et al.  What can exome sequencing do for you? , 2011, Journal of Medical Genetics.

[14]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[15]  B. Zhu,et al.  H3K36 Methylation Antagonizes PRC2-mediated H3K27 Methylation* , 2011, The Journal of Biological Chemistry.

[16]  D. Reinberg,et al.  The Structure of NSD1 Reveals an Autoregulatory Mechanism Underlying Histone H3K36 Methylation* , 2010, The Journal of Biological Chemistry.

[17]  K. Mokbel,et al.  Evidence for a tumour suppressor function of SETD2 in human breast cancer: a new hypothesis. , 2010, Anticancer research.

[18]  Gerben Duns,et al.  Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. , 2010, Cancer research.

[19]  Hong Li,et al.  Histone H3 lysine 36 methyltransferase Hypb/Setd2 is required for embryonic vascular remodeling , 2010, Proceedings of the National Academy of Sciences.

[20]  J. Ahringer,et al.  Differential chromatin marking of introns and expressed exons by H3K36me3 , 2008, Nature Genetics.

[21]  K. Jones,et al.  The Iws1:Spt6:CTD complex controls cotranscriptional mRNA biosynthesis and HYPB/Setd2-mediated histone H3K36 methylation. , 2008, Genes & development.

[22]  L. Mahadevan,et al.  Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation , 2007, The EMBO journal.

[23]  V. Cormier-Daire,et al.  Sotos syndrome , 2007, Orphanet journal of rare diseases.

[24]  T. Mikkelsen,et al.  Genome-wide maps of chromatin state in pluripotent and lineage-committed cells , 2007, Nature.

[25]  N. Rahman,et al.  Mutations in RNF135, a gene within the NF1 microdeletion region, cause phenotypic abnormalities including overgrowth , 2007, Nature Genetics.

[26]  Dustin E. Schones,et al.  High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.

[27]  T. Kouzarides Chromatin Modifications and Their Function , 2007, Cell.

[28]  Bing Li,et al.  Histone H3 Methylation by Set2 Directs Deacetylation of Coding Regions by Rpd3S to Suppress Spurious Intragenic Transcription , 2005, Cell.

[29]  A. Munnich,et al.  Clinical and molecular overlap in overgrowth syndromes , 2005, American journal of medical genetics. Part C, Seminars in medical genetics.

[30]  Xing Zhang,et al.  The SET-domain protein superfamily: protein lysine methyltransferases , 2005, Genome Biology.

[31]  N. Rahman,et al.  Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations. , 2005, American journal of human genetics.

[32]  A. Munnich,et al.  Spectrum of NSD1 mutations in Sotos and Weaver syndromes , 2003, Journal of medical genetics.

[33]  J. Cheng,et al.  A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. , 2001, Blood.

[34]  S. Henikoff,et al.  Predicting deleterious amino acid substitutions. , 2001, Genome research.

[35]  T. Cole,et al.  Sotos syndrome: a study of the diagnostic criteria and natural history. , 1994, Journal of medical genetics.

[36]  T. Cole,et al.  Small cell lung carcinoma in a patient with Sotos syndrome: are genes at 3p21 involved in both conditions? , 1992, Journal of medical genetics.

[37]  J. Fryns,et al.  Sotos syndrome and de novo balanced autosomal translocation (t(3;6)(p21;p21)) , 1990, Clinical genetics.

[38]  David W. Smith,et al.  A new overgrowth syndrome with accelerated skeletal maturation, unusual facies, and camptodactyly. , 1974, The Journal of pediatrics.

[39]  J. Crawford,et al.  Cerebral Gigantism in Childhood , 1964 .

[40]  K. Pollard,et al.  Detection of nonneutral substitution rates on mammalian phylogenies. , 2010, Genome research.

[41]  N. Rahman,et al.  NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes. , 2003, American journal of human genetics.

[42]  黒滝 直弘 私の論文から Haploinsufficiency of NSD1 causes Sotos syndrome , 2003 .

[43]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..

[44]  J. Crawford,et al.  CEREBRAL GIGANTISM IN CHILDHOOD. A SYNDROME OF EXCESSIVELY RAPID GROWTH AND ACROMEGALIC FEATURES AND A NONPROGRESSIVE NEUROLOGIC DISORDER. , 1964, The New England journal of medicine.